Molecular Differences Between Left-Sided Colon and Rectal Cancers

Article

This video examines a pair of studies that looked at molecular variances and clinical differences between left-sided colon and rectal cancers.

 

In this video, Mohamed E. Salem, MD, discusses a pair of studies presented at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

The first study looked at 1,457 primary colorectal cancers and examined molecular variances (abstract 522) between left-sided colon and rectal tumors, including differences in gene mutation frequency, protein expression, tumor mutational load, and microsatellite instability.

The second study (abstract 675) looked at clinical differences in patients with left-sided colon and rectal cancers and suggests that tumors in the rectum may carry distinct clinical characteristics.

Recent Videos
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content